| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034074228 |
| P356 | DOI | 10.1038/NM0403-393 |
| P698 | PubMed publication ID | 12669056 |
| P5875 | ResearchGate publication ID | 10827915 |
| P50 | author | John R. Mascola | Q63302442 |
| David C. Montefiori | Q63302725 | ||
| P2860 | cites work | The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 |
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants | Q33850415 | ||
| Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. | Q34349343 | ||
| Prospects for vaccine protection against HIV-1 infection and AIDS. | Q34542236 | ||
| Antigenic Shift of Visna Virus in Persistently Infected Sheep | Q34987372 | ||
| Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. | Q45849314 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 393-394 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Nature medicine | Q1633234 |
| P1476 | title | HIV-1: nature's master of disguise | |
| P478 | volume | 9 |
| Q92842963 | B-cell restriction - an alternative piece to the puzzle |
| Q33393641 | Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms |
| Q36614954 | Combination DNA plus protein HIV vaccines. |
| Q37484850 | Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection |
| Q35261990 | Functional fluorescent protein insertions in herpes simplex virus gB report on gB conformation before and after execution of membrane fusion. |
| Q36890344 | Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. |
| Q35140032 | Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa |
| Q38992744 | Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. |
| Q34396095 | Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q36986517 | HIV/AIDS vaccines: 2007. |
| Q37247974 | Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm |
| Q29619015 | Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies |
| Q92210244 | Impact of HIV-1 Diversity on Its Sensitivity to Neutralization |
| Q37729781 | Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. |
| Q60300903 | Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth |
| Q33810849 | Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab |
| Q38659790 | N-glycoprotein macroheterogeneity: biological implications and proteomic characterization. |
| Q41924059 | Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. |
| Q36246353 | Noninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q45417687 | Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. |
| Q39315316 | Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B′-infected former plasma donors from China naïve to antiretroviral therapy |
| Q35913867 | Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1. |
| Q33826682 | Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.